Experience
Chief Executive Officer
NAKI Therapeutics is an innovative research-focused biopharmaceutical company. Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147.
Our approach is to re-engineer NK cells-which belong to the human innate immune system to target the specific cancer cell surface marker CD147, and thereby kill the cancer cells more effectively and safely in comparison to existing treatments.
To deliver this therapy cost-effectively and in a scalable way, we also have developed proprietary methods to expand‘ memory-like’, highly potent, ‘off-the-shelf’ NK and CAR-NK cells fast and with high purity.
President & Co-founder
Experienced biopharmaceutical executive with 20+ years of leadership experience driving transformational change for global clinical development portfolios from early stage R&D to commercialization. Extensive background in healthcare economics and managed markets, with a keen understanding of how to position and value products to patients, providers, and payers to successfully launch new drugs and position for patient access and reimbursement coverage.
Track record of creating significant value for companies ranging from start-up to large scale with accomplishments that include building a company based on a molecule to managing a diverse global portfolio at a Top 3 pharma company.
Demonstrated a unique ability to identify innovative opportunities and technologies to extend patents, identify new indications and create strategic roadmaps that maximize long-term value given trial timing, costs, and potential for expansion.
Experienced in allocating budgets and salesforce capabilities given market opportunities and market penetration goals, and she has launched tactics across both physician and patient audiences to drive product trial and usage.
Founder & President
Stella is a Founder of MaiCell Therapeutics, an innovative xenotransplantation cell-based technology company, Agile Consulting Group and Business Founder of NAKI Therapeutics. Stella served in c-suite roles for Scaled Microbiomics and Diverse Biotech, and held commercial leadership positions with Merck & Co. Catalent Pharma (CDMO), Purdue Pharma, Jazz Pharmaceuticals, Assertio Therapeutics. Stella maintains active Board/ Advisory positions with multiple pharma companies and serves an advisor to numerous Universities on identifying and creating start up opportunities from existing IP.
